Clinical Experience With Sparsentan in Switzerland in IgA Nephropathy
ConditionIgA Nephropathy (IgAN)
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorWaid City Hospital, Zurich
About this trial
An observational study tracking the clinical course of patients with IgA nephropathy.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
IgA Nephropathy, Use of Sparsentan
Disqualifiers
age < 18y
Trial population
Patients with IgA Nephropathy and therapy with sparsentan
Trial design
Design model
Cohort
Time perspective
Retrospective
Treatments tested in this trial
sparsentan
DrugFollow up observation of patients with IgA Nephropathy on sparsentan regarding Albuminuria and GFR
sparsentan
Drugfollow up observation of Albuminuria and GFR in IgA patients in therapy with sparsentan
Treatment groups
50 Participants
are divided into 1 treatment groupGroup A: Patients with IgA Nephropathie and a therapy with Sparsentan1 intervention
Trial outcomes
Primary outcomes
1
Change of Albuminuria
What is the impact of sparsentan on Albuminuria
Time frame
36 monthsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: